{"changeSha256":"4025caf21efe1e884cb766e871f482d02e4cc8f6ff54f1f133e172ce4f137d7b","changedAt":"2026-07-27","changedFields":[{"after":"A GLP-1 receptor agonist component. This profile cites a U.S. combination-product label.","before":"A GLP-1 receptor agonist component represented by one exact U.S. combination-product label record.","field":"Profile summary"}],"currentVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/lixisenatide/versions/2/","version":2},"id":"profile:lixisenatide:v2","interpretationBoundary":"This event describes a PeptideScanner public-version change. It does not by itself establish that the cited source changed, that a scientific conclusion changed, or that source monitoring is continuous.","kind":"profile-updated","notice":"We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.","peptideSlugs":["lixisenatide"],"previousChangeEvent":null,"previousVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/lixisenatide/versions/1/","version":1},"schemaVersion":"peptidescanner-public-correction-lineage-event/v1","sourceRecords":[{"id":"dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25","name":"DailyMed · U.S. National Library of Medicine","sourceClass":"A","title":"SOLIQUA 100/33 (insulin glargine and lixisenatide) injection · SPL version 25 · published 2026-03-20","url":"https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=4bba538b-cf7c-4310-ae8f-cb711ed21bcc&version=25","verifiedAt":"2026-07-22"}],"subject":{"slug":"lixisenatide","type":"profile"}}